(February 2015) Crossbeta to supply PerkinElmer stable oligomers for use as AlphaLISA® analytes. Crossbeta Biosciences announced that PerkinElmer, Inc. has chosen Crossbeta’s stable oligomers for inclusion as reference standards in certain AlphaLISA® Research Immunoassay kits. The relationship has been initiated by joint activities on beta-amyloid 1-42-related applications with the option to expand to other protein oligomers. So-called beta-amyloid oligomers play an important role in Alzheimer’s disease pathology. Read more
(December 2014) We added three new posters highlighting our stable amyloid beta 1-42 oligomers to the publications section.
WHERE TO MEET US
BioEurope Spring 2015 (March 9-11 in Paris)
AD/PD 2015 (March 18-22 in Nice).
Stabilizing oligomers and targeting toxic oligomers is the basis for Crossbeta's oligomer drug discovery platforms which are accessible for partnering in therapeutic areas such as Alzheimer's, Parkinson's, Huntington and Diabetes Type 2.
In our Alzheimer program we have recently completed a high throughput screening campaign with 100,000 compounds resulting in the selection of 5 hit classes with >50% neutralizing effect on oligomer-induced neurotoxicity.
Stable oligomers can also be used as reference in biomarker assays.